Literature DB >> 28082049

Evolution and Increasing Complexity of the Therapeutic Landscape in Advanced Non-Small-cell Lung Cancer.

David R Gandara1, Jonathan W Riess2, Karen Kelly2, Tianhong Li2, Philip C Mack2, Primo N Lara2.   

Abstract

The therapeutic landscape in advanced non-small-cell lung cancer (NSCLC) is rapidly changing. Never have so many changes of major importance occurred within so short a time. The present perspective describes this rapid evolution and resultant increasing complexity in the therapeutic decision-making process for the practicing oncologist.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Epidermal growth factor receptor; NSCLC; Targeted therapy; Therapeutic landscape; Tyrosine kinase inhibitor

Mesh：

Substances：

Year:  2016        PMID： 28082049     DOI： 10.1016/j.cllc.2016.12.011

Source DB:  PubMed          Journal:  Clin Lung Cancer        ISSN： 1525-7304            Impact factor:   4.785


  5 in total

1.  Bone turnover biomarkers identify unique prognostic risk groups in men with castration resistant prostate cancer and skeletal metastases: Results from SWOG S0421.

Authors:  P N Lara; M Plets; C Tangen; E Gertz; N J Vogelzang; M Hussain; P W Twardowski; M G Garzotto; J P Monk; M Carducci; A Goldkorn; P C Mack; I Thompson; M Van Loan; D I Quinn
Journal:  Cancer Treat Res Commun       Date:  2018-04-28

2.  Targeted Next-Generation Sequencing Reveals Exceptionally High Rates of Molecular Driver Mutations in Never-Smokers With Lung Adenocarcinoma.

Authors:  Philip C Mack; Michael I Klein; Kristin L Ayers; Xiang Zhou; Sunny Guin; Marc Fink; Michael Rossi; Hussam Ai-Kateb; Timmy O'Connell; Feras M Hantash; William K Oh; Scott Newman; Eric E Schadt; Rong Chen; Fred R Hirsch
Journal:  Oncologist       Date:  2022-06-08       Impact factor: 5.837

3.  Clinician perspectives on clinical decision support systems in lung cancer: Implications for shared decision-making.

Authors:  Anshu Ankolekar; Britt van der Heijden; Andre Dekker; Cheryl Roumen; Dirk De Ruysscher; Bart Reymen; Adriana Berlanga; Cary Oberije; Rianne Fijten
Journal:  Health Expect       Date:  2022-05-10       Impact factor: 3.318

4.  METTL7B serves as a prognostic biomarker and promotes metastasis of lung adenocarcinoma cells.

Authors:  Rong Li; Chen Mu; Yundi Cao; Yingrui Fan
Journal:  Ann Transl Med       Date:  2022-08

5.  IL-33 blockade suppresses tumor growth of human lung cancer through direct and indirect pathways in a preclinical model.

Authors:  Kailing Wang; Shan Shan; Zongjun Yang; Xia Gu; Yuanyuan Wang; Chunhong Wang; Tao Ren
Journal:  Oncotarget       Date:  2017-08-02
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.